CA2494211A1 - Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration - Google Patents
Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration Download PDFInfo
- Publication number
- CA2494211A1 CA2494211A1 CA002494211A CA2494211A CA2494211A1 CA 2494211 A1 CA2494211 A1 CA 2494211A1 CA 002494211 A CA002494211 A CA 002494211A CA 2494211 A CA2494211 A CA 2494211A CA 2494211 A1 CA2494211 A1 CA 2494211A1
- Authority
- CA
- Canada
- Prior art keywords
- anecortave acetate
- treatment
- patients
- visual acuity
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004304 visual acuity Effects 0.000 title claims abstract description 27
- 206010064930 age-related macular degeneration Diseases 0.000 title claims abstract description 13
- 229960001232 anecortave Drugs 0.000 title claims description 67
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 title claims description 65
- 208000002780 macular degeneration Diseases 0.000 title abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000003902 lesion Effects 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims 10
- -1 compound anecortave acetate Chemical class 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 71
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- 230000004438 eyesight Effects 0.000 description 31
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 22
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 201000004569 Blindness Diseases 0.000 description 15
- 230000004393 visual impairment Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 238000004321 preservation Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 7
- 230000000964 angiostatic effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 231100001035 ocular change Toxicity 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 4
- 229940061392 visudyne Drugs 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000279 safety data Toxicity 0.000 description 3
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010024214 Lenticular opacities Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical group O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 230000004412 visual outcomes Effects 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000022749 pupil disease Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40122002P | 2002-08-05 | 2002-08-05 | |
| US60/401,220 | 2002-08-05 | ||
| PCT/US2003/020154 WO2004012742A1 (en) | 2002-08-05 | 2003-06-26 | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2494211A1 true CA2494211A1 (en) | 2004-02-12 |
Family
ID=31495940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002494211A Abandoned CA2494211A1 (en) | 2002-08-05 | 2003-06-26 | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040127472A1 (https=) |
| EP (1) | EP1539182A4 (https=) |
| JP (1) | JP2005535691A (https=) |
| KR (1) | KR20050026510A (https=) |
| CN (1) | CN1674913A (https=) |
| AR (1) | AR040599A1 (https=) |
| AU (1) | AU2003281817A1 (https=) |
| BR (1) | BR0313546A (https=) |
| CA (1) | CA2494211A1 (https=) |
| DE (1) | DE03742226T1 (https=) |
| ES (1) | ES2244361T1 (https=) |
| MX (1) | MXPA05000773A (https=) |
| PL (1) | PL375024A1 (https=) |
| RU (1) | RU2322239C2 (https=) |
| TW (1) | TW200410699A (https=) |
| WO (1) | WO2004012742A1 (https=) |
| ZA (1) | ZA200500731B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| MXPA05008396A (es) * | 2003-02-20 | 2006-03-30 | Alcon Inc | Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica. |
| AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
| US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| CN101759741B (zh) * | 2008-11-06 | 2013-01-09 | 天津金耀集团有限公司 | 一种化合物及其在制备治疗血管新生的药物中的应用 |
| CN101923856B (zh) | 2009-06-12 | 2012-06-06 | 华为技术有限公司 | 语音识别训练处理、控制方法及装置 |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| RU2489146C1 (ru) * | 2012-07-11 | 2013-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения "сухой" формы возрастной макулярной дегенерации |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| RU2051651C1 (ru) * | 1988-07-07 | 1996-01-10 | Институт химии поверхности АН Украины | Основа для глазных капель |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
| ATE283013T1 (de) * | 1999-10-21 | 2004-12-15 | Alcon Inc | Medikamentenzuführvorrichtung |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US20040127472A1 (en) * | 2002-08-05 | 2004-07-01 | Jerdan Janice A. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
-
2003
- 2003-06-26 US US10/606,501 patent/US20040127472A1/en not_active Abandoned
- 2003-06-26 PL PL03375024A patent/PL375024A1/xx unknown
- 2003-06-26 JP JP2004526013A patent/JP2005535691A/ja active Pending
- 2003-06-26 MX MXPA05000773A patent/MXPA05000773A/es not_active Application Discontinuation
- 2003-06-26 US US10/521,707 patent/US20060166956A1/en not_active Abandoned
- 2003-06-26 DE DE03742226T patent/DE03742226T1/de active Pending
- 2003-06-26 KR KR1020057001248A patent/KR20050026510A/ko not_active Ceased
- 2003-06-26 ES ES03742226T patent/ES2244361T1/es active Pending
- 2003-06-26 WO PCT/US2003/020154 patent/WO2004012742A1/en not_active Ceased
- 2003-06-26 AU AU2003281817A patent/AU2003281817A1/en not_active Abandoned
- 2003-06-26 BR BR0313546-2A patent/BR0313546A/pt not_active IP Right Cessation
- 2003-06-26 RU RU2005106234/14A patent/RU2322239C2/ru not_active IP Right Cessation
- 2003-06-26 EP EP03742226A patent/EP1539182A4/en not_active Withdrawn
- 2003-06-26 CN CNA038188260A patent/CN1674913A/zh active Pending
- 2003-06-26 CA CA002494211A patent/CA2494211A1/en not_active Abandoned
- 2003-07-07 TW TW092118474A patent/TW200410699A/zh unknown
- 2003-07-17 AR AR20030102575A patent/AR040599A1/es unknown
-
2005
- 2005-01-25 ZA ZA200500731A patent/ZA200500731B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR040599A1 (es) | 2005-04-13 |
| BR0313546A (pt) | 2005-07-12 |
| ZA200500731B (en) | 2006-08-30 |
| RU2005106234A (ru) | 2005-08-10 |
| KR20050026510A (ko) | 2005-03-15 |
| US20060166956A1 (en) | 2006-07-27 |
| AU2003281817A1 (en) | 2004-02-23 |
| MXPA05000773A (es) | 2005-04-19 |
| CN1674913A (zh) | 2005-09-28 |
| TW200410699A (en) | 2004-07-01 |
| WO2004012742A1 (en) | 2004-02-12 |
| US20040127472A1 (en) | 2004-07-01 |
| PL375024A1 (en) | 2005-11-14 |
| DE03742226T1 (de) | 2006-03-09 |
| ES2244361T1 (es) | 2005-12-16 |
| JP2005535691A (ja) | 2005-11-24 |
| EP1539182A1 (en) | 2005-06-15 |
| EP1539182A4 (en) | 2010-01-20 |
| RU2322239C2 (ru) | 2008-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anecortave Acetate Clinical Study Group | Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy | |
| Anecortave Acetate Clinical Study Group | Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes | |
| Yeung et al. | Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone | |
| Chalam et al. | Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma | |
| Jonas | Intravitreal triamcinolone acetonide for diabetic retinopathy | |
| Whitcup et al. | Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis | |
| RU2572707C2 (ru) | Глазные капли с дифлупреднатом для лечения отека желтого пятна | |
| Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
| MXPA04004363A (es) | Procedimientos para tratar enfermedades neovasculares oculares. | |
| CA2494211A1 (en) | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| Kandarakis et al. | One-year randomized comparison of safety and efficacy of trabeculectomy with mitomycin C sub-tenon injection versus mitomycin C-infused sponges | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| Ha et al. | Efficacy and safety of intracameral bevacizumab for treatment of neovascular glaucoma | |
| Kaback et al. | Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5% | |
| Hyung et al. | Midd-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| Malone et al. | Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma | |
| Paganelli et al. | A single intraoperative sub-tenon’s capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery | |
| Denkel et al. | Influence of mitomycin C on the therapeutic success of stand-alone Xen45 gel stents and its combination with cataract surgery in open-angle glaucoma patients | |
| Albialy et al. | Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery | |
| Paccola et al. | Anti‐inflammatory efficacy of a single posterior subtenon injection of triamcinolone acetonide versus prednisolone acetate 1% eyedrops after pars plana vitrectomy | |
| Pérez-Sarriegui et al. | Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant | |
| Gull et al. | Intravitrealversus posterior subtenon triamcinolone acetonide in conjunction with intravitreal bevacizumab for refractory diabetic macular edema | |
| Fung | A novel sustained-release intravitreal drug delivery system for retinal vascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |